Recludix Pharma Collaborated with Sanofi to Boost Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications
- Recludix will receive $125M in near-term fees and is eligible to receive ~$1.2B in development, regulatory & sales milestones along with royalties on future product sales
- Sanofi will have global rights to small molecule STAT6 inhibitors & will lead clinical development and commercialization responsibilities globally. Recludix gets an option to participate equally in US profit/loss, and co-promotion activities for the partnered product in the US
- Recludix will also advance STAT6 inhibitors from preclinical research and development until the start of P-II clinical trials & is also advancing STAT3 inhibitors for Th17-mediated I&I diseases and oncology indications, as well as additional programs
Ref: Globenewswire | Image: Sanofi
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.